Join Eupraxia Pharmaceuticals for a virtual key opinion leader (KOL) event featuring Waqqas Afif, MD, MSc (Epi), FRCP(C) (McGill University), and Mark DeLegge, MD, FACG, CNSP, AGAF, FASGE (IQVIA), who will join company management to discuss EP-104GI for the treatment of eosinophilic esophagitis (EoE).

The event will provide an overview of endoscopies and the administration of EP-104GI, a long-acting submucosal corticosteroid formulation to be injected within esophageal tissues and design to have sustained, localized drug release within esophageal tissue. The presentation will also review endoscopy practices in the U.S., and management will discuss primary market research on incorporating EP-104GI into current GI practices.

A live question and answer session will follow the formal presentations.